Takeda Group's Gammagard (Notice of Intent to Sole Source)
Open — responses due 16 Nov 2026 (2 days left) · No Set aside used · National Institutes of Health (NIH), HHS · MD · NAICS 3254 · Solicitation NOI-27-000636
Get the AI read before you spend a day on this package. FedSift pulls out the deal-breakers and key risks, each quoted from the document. Free, no account.
Likely sole source (FedSift estimate from the notice text) — confirm on SAM.gov before investing in a bid
AI read of this solicitation
Before you spend a day on this package: FedSift reads every document and pulls out what is being bought, the deal-breakers and the key risks — each quoted from the page it came from. Free, no account needed. The result is shared, so the next reader gets it instantly. With a free account it also builds the full compliance matrix.
Track this solicitation
We'll email you if the response deadline moves, an amendment posts, or new documents are added. It closes 16 November 2026. No account needed — one email, unsubscribe in a click.
Description
Acquisition Description: This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with Takeda Pharmaceutical Company Limited. The National Institutes of Health (NIH) Clinical Center (CC) is a clinical research hospital providing all medical services for patients participating in human research protocols of the NIH. The CC Pharmacy department provides a range of pharmaceutical care services to inpatients and outpatients enrolled in clinical trials. The CC Pharmacy department is responsible for acquiring the supply of medications required for patient care. This includes the purchase of Gammagard S/D 10gm and Gammagard S/D 5gm kits. The NIH CC Pharmacy is requesting the purchase of 10 bottles each of Gammagard S/D 10gm and Gammagard S/D 5gm kits and as needed to provide anticipated current patient care need. Justification: TAKEDA Group is the only responsible source for Gammagard S/D. There are multiple patients in the NIH currently on therapy with Gammagard S/D and additional patients may be transferred to the NIH for evaluation and treatment. Gammagard S/D is on the Clinical Center’s formulary, requiring a supply to be available in the Pharmacy Department at all times to support ongoing patient care. The NIH needs to keep using the same items to keep treatment consistent.
Go deeper on this solicitation
FedSift reads the full solicitation package — every attachment — and pre-extracts the compliance matrix, evaluation factors, key risks, win themes and deal-breakers, each with a verbatim quote and the exact PDF page it came from. It scores the opportunity against your company profile, tells you whether to bid as prime or sub, and ranks teaming partners who could close your gaps.
Source: this notice on SAM.gov. FedSift republishes public federal procurement data and is not affiliated with the U.S. Government. Always confirm dates and requirements against SAM.gov before responding.
